Cost-effectiveness analysis of neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced esophageal squamous cell carcinoma based on the NEOCRTEC5010 trial-Reference-Cited by-同舟云学术

Cost-effectiveness analysis of neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced esophageal squamous cell carcinoma based on the NEOCRTEC5010 trial

Published:2019-12 Issue: Volume:141 Page:27-32
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Zhan Mei,Zheng Hanrui,Yang Yu,Xu Ting,Li Qiu^ORCID

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology

Reference28 articles.

1. Cancer statistics in China, 2015;Chen;CA Cancer J Clin,2016

2. Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China;Tran;Int J Cancer,2005

3. Esophageal carcinoma advances in treatment results for locally advanced disease: review;Herskovic;Ann Oncol,2012

4. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus;Bosset;N Engl J Med,1997

5. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901;Mariette;J Clin Oncol,2014

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness Analysis of Toripalimab Plus Paclitaxel and Cisplatin as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma;Advances in Therapy;2023-01-09

2. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery in patients with locally advanced esophageal squamous cell carcinoma who achieved clinical complete response when induction chemoradiation finished: A phase II random;Radiotherapy and Oncology;2022-09

3. Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China;Frontiers in Public Health;2022-06-29

4. A cost-effectiveness modeling study of treatment interventions for stage I to III esophageal squamous cell carcinoma;Cost Effectiveness and Resource Allocation;2022-04-02

5. Neoadjuvant Therapy Versus Upfront Surgery for Patients With Clinical Stage 2 or 3 Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis;Annals of Surgical Oncology;2022-01-11